GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.
| Revenue (Most Recent Fiscal Year) | $147.17M |
| Net Income (Most Recent Fiscal Year) | $-408.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.27 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -363.18% |
| Net Margin (Trailing 12 Months) | -277.46% |
| Return on Equity (Trailing 12 Months) | -17.11% |
| Return on Assets (Trailing 12 Months) | -14.75% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $66.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.44 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-11.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 41.02M |
| Free Float | -- |
| Market Capitalization | $2.10B |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | 4.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |